查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1616802

再生医疗的全球市场:产品，治疗领域，各地区，2024年～2031年

Global Regenerative Medicine Market By Product, Therapeutic Area, & Region for 2024-2031
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

再生医学市场评估，2024-2031

大众越来越认识到预防性和个人化医疗在控制癌症、中枢神经系统疾病等流行慢性疾病方面的益处，正在推动再生医学市场的成长潜力。 Verified Market Research 的分析师表示，到 2031 年，再生医学市场的价值将超过预期的 1,734.9 亿美元，到 2024 年的营收将达到 327.1 亿美元。

人口老化加剧导致的疾病负担增加是再生医学市场的主要驱动力。当前医疗保健格局变化的趋势预计将随着时间的推移而扩大，使市场从 2024 年到 2031 年的复合年增长率达到 23.19%。

再生医学市场定义/概述

再生医学是一个先进的医学领域，专注于利用人体先天的癒合和修復能力。我们使用现代程序来刺激和替换受损的组织和器官，以恢復正常功能。一项重要的策略是使用干细胞。干细胞具有分化成多种细胞类型的独特能力。在再生医学中，科学家和医生利用这些细胞来修復或替换因受伤、疾病或老化而受损的组织。

此外，治疗心臟病和关节损伤、再生皮肤，甚至培养用于移植的器官只是再生医学众多应用中的一小部分。其目的是透过培养人体固有的治癒能力并为各种健康问题提供创造性的解决方案来改变医疗干预措施。

慢性疾病的蔓延会导致再生医学销售量激增吗？

随着癌症、心血管疾病、神经系统疾病等盛行率的增加，需要特殊的医疗照护来解决根本原因并提供改变疾病甚至治癒的可能性。因此，慢性病的盛行率不断增加，这是推动再生医学市场成长的主要因素。

基因编辑、干细胞工程和 3D 生物列印的快速进展将加速更有效和定製药物的开发。这些突破将扩大可治疗的疾病类型，提高治疗准确性，改善患者的整体治疗效果，并将再生医学推向市场医疗保健主流。

此外，政府增加对药物发现研究和开发的支持和资助对于再生医学的扩张至关重要。创投、製药公司和政府机构也提供了越来越多的财政支持，以提高此类护理的生产力。除此之外，製药业的财务稳定性正在导致更快的临床研究、更大的患者群体和更快的市场渗透，所有这些都促进了再生医学市场的成长。

高昂的製造成本和复杂的製造流程如何影响再生医学市场？

复杂的监管系统，加上细胞和基因疗法的安全问题，使得审批过程既耗时又昂贵。因此，严格的监管和冗长的审批流程是限制再生医学市场成长的障碍。

再生医学市场面临着巨大的製造和可扩展性挑战，因为细胞和基因疗法涉及高昂的製造成本和复杂的製造程序。所用生物成分的脆弱性加剧了挑战，导致成本更高且患者接触受限。

此外，这些治疗的高昂成本限制了患者的治疗并对医疗保健系统造成压力。鑑于再生医学的高昂前期成本和短期数据，不成熟的报销政策和保险公司不愿承担费用是限制其采用的主要挑战。

目录

第1章 全球再生医疗市场:简介

  • 市场概要
  • 调查范围
  • 前提条件

第2章 摘要整理

第3章 VERIFIED MARKET RESEARCH的调查手法

  • 资料探勘
  • 检验
  • 主要采访
  • 资料来源一览

第4章 全球再生医疗市场展望

  • 概要
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • 波特的五力分析
  • 价值链分析

第5章 再生医疗的全球市场:各产品

  • 概要
  • 治疗药
  • 细胞疗法
    • 干细胞治疗
    • 细胞移植
  • 干细胞治疗产品
  • 细胞免疫疗法产品
  • 基因治疗
  • 组织工程

第6章 再生医疗的全球市场:各治疗领域

  • 概要
  • 肿瘤学
  • 肌肉骨骼系统疾病
  • 皮肤科·伤口护理
  • 心血管疾病
  • 眼科
  • 神经学
  • 其他的用途

第7章 再生医疗的全球市场:各地区

  • 概要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中东·非洲
    • 阿拉伯联合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲

第8章 全球再生医疗市场:竞争情形

  • 概要
  • 各公司的市场排行榜
  • 主要的开发策略
  • 企业的地区足迹
  • 企业的产业足迹
  • ACE矩阵

第9章 企业简介

  • Johnson & Johnson
  • Novartis
  • Roche
  • AbbVie
  • Pfizer
  • Vericel Corporation
  • Cellular Dynamics International
  • Editas Medicine
  • Spark Therapeutics
  • Bluebird bio

第10章 主要发展

  • 产品的上市/开发
  • 合併和收购
  • 事业扩大
  • 伙伴关係和合作

第11章 附录

  • 相关调查
简介目录
Product Code: 7157

Regenerative Medicine Market Valuation - 2024-2031

Growing public awareness regarding the benefits of preventative and personalized medicine in curbing prevalent chronic diseases such as cancer, central nervous diseases, and others drives the growth potential of the Regenerative Medicine Market. According to the analyst from Verified Market Research, the Regenerative Medicine Market is estimated to reach a valuation of USD 173.49 Billion by 2031, over the forecast by subjugating the revenue of USD 32.71 Billion valued in 2024.

The rising burden of diseases among the growing aging population is a key driver of the Regenerative Medicine Market. The current trend of shifting healthcare landscape is expected to grow over time enabling the market to grow at aCAGR of 23.19% from 2024 to 2031.

Regenerative Medicine Market: Definition/ Overview

Regenerative medicine is an advanced branch of medicine that focuses on using the body's natural ability to heal and repair itself. It involves using modern procedures to stimulate or replace damaged tissues and organs to restore normal function. One important strategy is the utilization of stem cells, which have the unique capacity to differentiate into diverse cell types. In regenerative medicine, scientists and physicians use these cells to repair or replace damaged tissues caused by injury, disease, or aging.

Furthermore, treatments for heart problems and joint injuries, skin regeneration, and even the cultivation of organs for transplantation are just a few of the numerous applications for regenerative medicine. The aim is to transform medical interventions by fostering the body's inherent healing capacities and offering inventive resolutions for diverse health issues.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Prevalence of Chronic Illnesses Skyrocket the Sales of Regenerative Medicine?

The rising prevalence of conditions such as cancer, cardiovascular disease, and neurological disorders demands medicine that stands out by offering the potential for disease modification or even cure, addressing the root causes. As a result, the rising prevalence of chronic diseases poses a key driver resulting in a higher trajectory of growth in the Regenerative Medicine Market.

Rapid advancements in gene editing, stem cell engineering, and 3D bioprinting speed up the development of more effective and tailored medicines. These breakthroughs broaden the variety of treatable illnesses, improve treatment precision, and improve overall patient outcomes, propelling regenerative medicine to mainstream healthcare in the market.

Furthermore, growing government support and funding in the research and development of drug discovery are crucial for the expansion of regenerative medicine. There is also a rise in financial support offered by venture capitalists, pharmaceutical corporations, and government agencies in upsurging the productivity of this kind of medicine. In addition to this, financial stability in the pharmaceutical industry is leading to faster clinical studies, larger patient cohorts, and faster market penetration, all of which contribute to bolstering the growth of the Regenerative Medicine Market.

How are High Production Costs and Complex Manufacturing Processes Favoring the Regenerative Medicines Market?

The complexity of the regulatory systems, combined with safety concerns about cell and gene therapies, makes the authorization process lengthy and costly. Thus, stringent restrictions and lengthy approval processes are barriers restraining the growth of the Regenerative Medicine Market.

Due to the high production costs and intricate manufacturing procedures involved in cell and gene therapies, the Regenerative Medicine Market faces considerable challenges in terms of manufacturing and scalability. The fragile nature of the biological components used adds to the challenge, resulting in higher expenses and limited patient access.

Furthermore, the high expense of these therapies limits patient access and puts pressure on healthcare systems. The immature reimbursement policies and the unwillingness of insurance companies to cover the costs considering high upfront expenditures and short-term data of regenerative medicine are key challenges limiting its adoption.

Category-Wise Acumens

Will Prevalence Of Chronic Diseases Upsurge Application of Cell Therapy?

According to VMR, the cell therapy segment is estimated to hold the largest market share in the Regenerative Medicine Market during the forecast period. The targeted therapeutic potential, versatility, and personalized approach are features anticipated to boost the expansion of the market. The expansion and dominance of cell therapy in this rapidly evolving market are further propelled by the compliance of simplified and advanced procedures with a favorable regulatory environment is bolstering the use of cell therapy. In addition to this, the growing aging population susceptible to various diseases is resulting in an increase in healthcare cost, thereby demanding affordable regenerative medicines like cell therapies.

The versatility of cell therapies in treating a wide range of ailments, from cancer and autoimmune disorders to neurological and cardiovascular conditions, expands their market reach and potential impact, contributing to the segment's dominant position. Also, cell therapies differ from conventional pharmaceuticals as they adopt a focused approach to illness therapy, minimizing systemic effects and increasing efficacy while minimizing negative effects.

Furthermore, improvements in cell culture and manufacturing processes contribute toward enhancing the efficiency and scalability of cell therapy production, thereby resulting in higher accessibility and cost-effectiveness. Such technological advancements serve as an important role in bolstering the cell therapy segment in the Regenerative Medicine Market.

Which Factors Enhance the Use of Regenerative Medicine in Musculoskeletal Problems?

The musculoskeletal disorders segment is estimated to dominate in the Regenerative Medicine Market over the period. The high prevalence of this disease is creating a substantial demand for treatment options. Also, active research and development efforts have resulted in an efficient process of new cell and gene therapy applicants, firmly establishing musculoskeletal disorders as a dominant segment in the Regenerative Medicine Market.

Arthritis, osteoarthritis, sports injuries, and back discomfort affect a large proportion of the global population. The prevalence of musculoskeletal problems results in a sizable and expanding patient population, producing a high demand for effective treatment alternatives. As a result, the Regenerative Medicine Market has naturally oriented toward tackling the most common difficulties related to musculoskeletal disorders influencing the demand for regenerative medicine.

Furthermore, the high ailments associated with musculoskeletal diseases are spurring the demand for innovative treatments to relieve symptoms for providing long-term benefits. Thus, regenerative medicine therapies, with their ability to promote tissue repair and regeneration, offer a promising option for treating the underlying causes of many illnesses. This advantage is likely to enable the musculoskeletal disorder segment to dominate the market.

Country/Region-wise Acumens

How will Well-established Healthcare Infrastructure in North America Drive Regenerative Medicine Market?

According to VMR Analyst, North America is estimated to dominate the Regenerative Medicine Market during the forecast period. The dominance of this segment is attributable to the growing demand for personalized medicine with high compatibility with the current regulatory framework.

Also, the growing number of ailments related to the widespread adoption of social habits such as drinking, smoking, dietary changes, and sedentary lifestyles are leading to an increase in healthcare expenditure. This growing number of diseases among the demographic group, especially the aged population, is stirring the need for accurate and efficient regenerative medicines in the region.

A rising number of people are reaching older age groups, leading to an increased incidence of aging-related chronic disorders in the North American region. Regenerative medicine, with its ability to repair and replace damaged tissues, is ideal for the healthcare needs of an aging population, propelling market growth.

Furthermore, the United States Food and Drug Administration (FDA) established streamlined paths for cell and gene therapy approval, promoting faster regulatory approvals and market access. As a result, North America's advantageous regulatory structure, particularly in the United States, is a key driver of the Regenerative Medicine Market in North America.

What are the Key Drivers Influencing the Adoption of Regenerative Medicine in Asia Pacific?

Asia Pacific is estimated to grow at the highest CAGR in the Regenerative Medicine Market during the forecast period due to the high healthcare spending among large and growing patient populations wanting affordable therapies. This growing focus on using regenerative medicines to treat infectious diseases along with the support and funding of government-driven healthcare initiatives is likely to create a dynamic and developing market landscape with tremendous opportunities for innovation and success in this region.

Individuals and governments are increasingly able to invest in innovative and costly medical technology, such as regenerative medicines. This trend is projected to enable the expansion of the market and facilitate the adoption of innovative treatments in the region, propelling the demand for regenerative medicine.

Furthermore, the frequent occurrence of diseases such as hepatitis and dengue fever increases the demand for effective regenerative therapies in this area. Thus, growing awareness regarding the popularity and potential of regenerative medicine in combating diseases among governments and healthcare organizations in combating infectious diseases, resulting in increased investment and research in this field.

Competitive Landscape

The regenerative medicine sector is a battleground for innovation, with established pharmaceutical giants competing for domination alongside dynamic startups. While large firms have extensive portfolios and established distribution networks, versatile startups provide innovative platforms and individualized treatments. This dynamic landscape offers ongoing evolution and ground-breaking discoveries, delivering an exciting ride for both investors and patients.

Some of the prominent players operating in the Regenerative Medicine Market include:

Johnson & Johnson

Novartis

Roche

AbbVie

Pfizer

Vericel Corporation

Cellular Dynamics International, Editas Medicine

Spark Therapeutics

Bluebird bio

Fate Therapeutics

Autolus Therapeutics

Tmunity Therapeutics

Rocket Pharmaceuticals

Carbios Therapeutics

Regentis

Cellular Bioengineering (CBE) Korea

Athersys Inc.

ReNeuron

Histogenics

Regenerative Medicine Market Latest Developments

In January 2024, Vertex Pharmaceuticals has reported promising Phase 2b data for VX-886, a stem cell therapy for pulmonary fibrosis, showing increased lung function and breathing capacity in patients.

In January 2024, Rocket Pharmaceuticals has initiated a Phase 3 trial for its RVL001 stem cell therapy for alpha-1 antitrypsin deficiency (AATD), a rare genetic liver disease, marking a significant step towards commercialization and providing a potentially life-saving treatment for AATD sufferers.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL REGENERATIVE MEDICINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL REGENERATIVE MEDICINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porter's Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL REGENERATIVE MEDICINE MARKET, BY PRODUCT

  • 5.1 Overview
  • 5.2 Therapeutics
  • 5.3 Cell Therapy
    • 5.3.1 Stem cell Therapy
    • 5.3.2 Cell Transplantations
  • 5.4 Stem cell Therapy Products
  • 5.5 Cell-based Immunotherapy Products
  • 5.6 Gene Therapy
  • 5.7 Tissue Engineering

6 GLOBAL REGENERATIVE MEDICINE MARKET, BY THERAPY AREA

  • 6.1 Overview
  • 6.2 Oncology
  • 6.3 Musculoskeletal Disorders
  • 6.4 Dermatology & Wound Care
  • 6.5 Cardiovascular Diseases
  • 6.6 Ophthalmology
  • 6.7 Neurology
  • 6.8 Other applications

7 GLOBAL REGENERATIVE MEDICINE MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 The U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 The U.K.
    • 7.3.3 France
    • 7.3.4 Italy
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Argentina
    • 7.5.3 Rest of LATAM
  • 7.6 Middle East and Africa
    • 7.6.1 UAE
    • 7.6.2 Saudi Arabia
    • 7.6.3 South Africa
    • 7.6.4 Rest of the Middle East and Africa

8 GLOBAL REGENERATIVE MEDICINE MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies
  • 8.4 Company Regional Footprint
  • 8.5 Company Industry Footprint
  • 8.6 ACE Matrix

9 COMPANY PROFILES

  • 9.1 Johnson & Johnson
    • 9.1.1 Company Overview
    • 9.1.2 Company Insights
    • 9.1.3 Business Breakdown
    • 9.1.4 Product Benchmarking
    • 9.1.5 Key Developments
    • 9.1.6 Winning Imperatives
    • 9.1.7 Current Focus & Strategies
    • 9.1.8 Threat from Competition
    • 9.1.9 SWOT Analysis
  • 9.2 Novartis
    • 9.2.1 Company Overview
    • 9.2.2 Company Insights
    • 9.2.3 Business Breakdown
    • 9.2.4 Product Benchmarking
    • 9.2.5 Key Developments
    • 9.2.6 Winning Imperatives
    • 9.2.7 Current Focus & Strategies
    • 9.2.8 Threat from Competition
    • 9.2.9 SWOT Analysis
  • 9.3 Roche
    • 9.3.1 Company Overview
    • 9.3.2 Company Insights
    • 9.3.3 Business Breakdown
    • 9.3.4 Product Benchmarking
    • 9.3.5 Key Developments
    • 9.3.6 Winning Imperatives
    • 9.3.7 Current Focus & Strategies
    • 9.3.8 Threat from Competition
    • 9.3.9 SWOT Analysis
  • 9.4 AbbVie
    • 9.4.1 Company Overview
    • 9.4.2 Company Insights
    • 9.4.3 Business Breakdown
    • 9.4.4 Product Benchmarking
    • 9.4.5 Key Developments
    • 9.4.6 Winning Imperatives
    • 9.4.7 Current Focus & Strategies
    • 9.4.8 Threat from Competition
    • 9.4.9 SWOT Analysis
  • 9.5 Pfizer
    • 9.5.1 Company Overview
    • 9.5.2 Company Insights
    • 9.5.3 Business Breakdown
    • 9.5.4 Product Benchmarking
    • 9.5.5 Key Developments
    • 9.5.6 Winning Imperatives
    • 9.5.7 Current Focus & Strategies
    • 9.5.8 Threat from Competition
    • 9.5.9 SWOT Analysis
  • 9.6 Vericel Corporation
    • 9.6.1 Company Overview
    • 9.6.2 Company Insights
    • 9.6.3 Business Breakdown
    • 9.6.4 Product Benchmarking
    • 9.6.5 Key Developments
    • 9.6.6 Winning Imperatives
    • 9.6.7 Current Focus & Strategies
    • 9.6.8 Threat from Competition
    • 9.6.9 SWOT Analysis
  • 9.7 Cellular Dynamics International
    • 9.7.1 Company Overview
    • 9.7.2 Company Insights
    • 9.7.3 Business Breakdown
    • 9.7.4 Product Benchmarking
    • 9.7.5 Key Developments
    • 9.7.6 Winning Imperatives
    • 9.7.7 Current Focus & Strategies
    • 9.7.8 Threat from Competition
    • 9.7.9 SWOT Analysis
  • 9.8 Editas Medicine
    • 9.8.1 Company Overview
    • 9.8.2 Company Insights
    • 9.8.3 Business Breakdown
    • 9.8.4 Product Benchmarking
    • 9.8.5 Key Developments
    • 9.8.6 Winning Imperatives
    • 9.8.7 Current Focus & Strategies
    • 9.8.8 Threat from Competition
    • 9.8.9 SWOT Analysis
  • 9.9 Spark Therapeutics
    • 9.9.1 Company Overview
    • 9.9.2 Company Insights
    • 9.9.3 Business Breakdown
    • 9.9.4 Product Benchmarking
    • 9.9.5 Key Developments
    • 9.9.6 Winning Imperatives
    • 9.9.7 Current Focus & Strategies
    • 9.9.8 Threat from Competition
    • 9.9.9 SWOT Analysis
  • 9.10 Bluebird bio
    • 9.10.1 Company Overview
    • 9.10.2 Company Insights
    • 9.10.3 Business Breakdown
    • 9.10.4 Product Benchmarking
    • 9.10.5 Key Developments
    • 9.10.6 Winning Imperatives
    • 9.10.7 Current Focus & Strategies
    • 9.10.8 Threat from Competition
    • 9.10.9 SWOT Analysis

10 KEY DEVELOPMENTS

  • 10.1 Product Launches/Developments
  • 10.2 Mergers and Acquisitions
  • 10.3 Business Expansions
  • 10.4 Partnerships and Collaborations

11 Appendix

  • 11.1 Related Research